Chondrosarcoma Market Epidemiology, Growth Opportunities, and Pipeline Therapies and In-depth Analysis
Sarcomas are cancers that start in connective tissue, which are the body parts that have a supporting role in the body. The bones, cartilage, muscle, and blood are all types of connective tissue. Chondrosarcoma is a bone sarcoma that develops in the cartilage cells. It mostly affects adults above the age of 40 and the most common sites are the upper arm, pelvis, and thigh bone. Chondrosarcoma can be subdivided in several ways: by histologic grade, whether they arise de novo (primary) or from benign lesions (secondary), by location within the bone (central or peripheral), or by the syndrome.
As with many cancers, the cause of Chondrosarcoma is not clear. However, Chondrosarcoma is associated with certain genetic mutations. Some varieties of Chondrosarcoma arise from the transformation of benign cartilage lesions into cancers.
DelveInsight’s “Chondrosarcoma Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Chondrosarcoma, historical and forecasted epidemiology as well as the Chondrosarcoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Some of the key facts of the Chondrosarcoma Market Report:
According to the US Surveillance, Epidemiology and End Results Program, Chondrosarcoma contributes to 30% of different types of bone cancer
According to the American Cancer Society, Chondrosarcoma develops most often in adults, with an average age at diagnosis of 51. Less than 5% of cases occur in patients younger than 20
According to the researchers, Chondrosarcoma is slightly more common in males than in females
Bone tumors are rare diseases, and the Chondrosarcoma accounts for 25% to 40% of these tumors
In 7 MM the total prevalence of Chondrosarcoma is estimated to be around 5,000 to 6,000 diagnosed cases each year
Request a sample for the Report: https://www.delveinsight.com/sample-request/chondrosarcoma-market
People with Chondrosarcoma usually do not feel sick. They may be able to feel a bony bump, and most patients ultimately will have pain, swelling, or limited movement that is caused by the tumor. The symptoms of Chondrosarcoma include-
Joint stiffness
Pain gets worse over the time
Weakness and limited joint movement
Large lump (mass) on a bone
The feeling of pressure around the lump
Chondrosarcoma Market
The dynamics of the Chondrosarcoma market are anticipated to change in the coming years owing to the expected launch of emerging therapies such as INBRX-109, AG-120, and others during the forecasted period 2019-2032.
Learn more by requesting for sample @Chondrosarcoma Market Landscape
Chondrosarcoma Pipeline Therapies:
INBRX-109
Pazopanib
AG-120
Trabectedin
PD-1 inhibitor
Chondrosarcoma Pipeline Key Companies:
Genentech
Infinity Pharmaceuticals
Agios Pharmaceuticals
IGM Biosciences
Forma Therapeutics
Click here to read more about Chondrosarcoma Market Outlook 2032
Latest Reports by DelveInsight
Comments
Post a Comment